The present disclosure is directed to methods of modeling effectiveness of cancer therapeutics using live tissue from post-mortem cancer patient donors. Eligible cancer patient donors are identified and registered, along with relevant donor demographics and medical history. At least one tumor tissue sample is collected from each donor a predetermined period of time after donor death, where the tissue samples include dissociated cells and tissue sections. The samples are analyzed using one or more of in vitro, in vivo, ex vivo, and in silico models, either alone or in combination, to determine the effectiveness of at least one cancer therapeutic candidate. Donor diversity and increased sample size for tissue analysis increases the ability to identify promising therapeutic candidates relative to typical clinical trials.

Provided is a non-invasive method of detecting or screening for a cancer in a subject specimen originating in a tissue outside of the lung. The method includes detecting elevated levels of one or more carbonyl-containing volatile organic compounds (VOCs) that are biomarkers for the cancer in exhaled breath from the subject specimen. The method may further include obtaining exhaled breath from the subject specimen; forming adducts of the carbonyl-containing VOCs with a reactive chemical compound; quantifying the adducts of the carbonyl-containing VOCs to establish a subject value for each of the adducts; and comparing each subject value to a threshold healthy specimen value for each of the adducts of the carbonyl-containing VOCs. One or more subject values at quantities greater than threshold healthy specimen values are also useful for screening for the cancer in the subject specimen.

Disclosed herein is a method of analyzing flow cytometry data for cells derived from homogenized whole tumor samples.

Provided are: a novel anti-ROR1 antibody; a bispecific antibody comprising the anti-ROR1 antibody; and uses thereof.

Methods are provided for assessing risk of developing esophageal adenocarcinoma in a subject using one or more of the following marker genes/proteins: ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. Methods are also provided for determining expression of one or more esophageal adenocarcinoma risk factors in a subject. Methods are also provided for treating esophageal adenocarcinoma in a subject, for preventing esophageal adenocarcinoma in a subject, for inhibiting or decreasing proliferation of esophageal adenocarcinoma cells, for inhibiting or decreasing migration of esophageal adenocarcinoma cells, or for increasing susceptibility to cytotoxicity or inducing cell death of esophageal adenocarcinoma cells.

The present invention provides methods, systems, and kits for determining responsiveness of a subject with or susceptible to cancer to anti-PD1 immune checkpoint inhibitor immunotherapy (ICII) including determining the level of one or more of markers CD15 in CD8+Ki67/CD71+ or CD8/CD4Ki67/CD71+ T cells, CTLA-4 in CD4+Ki67/CD71+ T cells, FoxP3 in CD4+Ki67/CD71+ T cells, Ki67 or CD71 in CD8+ T cells, wherein an increase in CD15, CTLA-4, FoxP3, or a decrease in Ki67 or CD71 prior to immunotherapy is indicative that the subject is responsive to immunotherapy, particularly PD1 ICII.

Disclosed herein are compositions, systems, and methods for identifying subjects who may be responsive to MHC-I-dependent immunotherapeutic agents based upon the expression of the components of the antigen presentation machinery and, in particular, the expression of the constituent elements of the transporter associated with antigen processing complex and the major histocompatibility complex class I.

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

Provided are methods for identifying tumor-derived extracellular vesicles. The methods can include combining an antibody and a sample under conditions suitable for formation of antigen-antibody complexes with tumor-derived extracellular vesicles. The methods also include exposing the tumor-derived extracellular vesicles to a compound that binds beta-sheet structures, and determining if there is a change in binding of the compound to the extracellular vesicles compared to one or more controls.

Present invention relates to novel antibodies and their use in an improved method of determining and detecting C4d.